Risperidone Augmentation for PTSD
Placebo-Controlled Trial of Risperidone Augmentation for SSRI-Resistant Civilian PTSD
Sponsor: Duke University
This PHASE2/PHASE3 trial investigates Post-Traumatic Stress Disorder and is currently completed. Duke University leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
First recorded
Apr 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Duke University
- Janssen Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Atlanta, United States
- • Charleston, United States